Cell Viability in HCM
Cell-based study · HCM [1]
HCM were treated with Rosuvastatin at the tested concentrations for 24 h, with normal culture medium without statins serving as the control. Rosuvastatin did not reduce cell viability with increasing concentrations.
| Endpoint | Reported result | Reference |
|---|---|---|
| cell viability | Reported result 0, 10, 20, 40, 80 and 160 μM; 24 h: atorvastatin and lovastatin reduced cell viability with increasing concentrations of statins in HCM, C2C12 and HUVEC, while rosuvastatin and pravastatin did not. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 10, 20, 40, 80 and 160 μM
- Exposure duration
- 24 h
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Rosuvastatin
The paper names Rosuvastatin without stating the salt or form; not verified as the calcium form supplied as A10810. No dose conversion or lot validation.
Materials and Methods > Cell Culture and Drug Treatments (S5); Materials and Methods > Cell Viability Assay (S8, S9, S10); Results > Ferroptosis Contributes to Atorvastatin-Induced Cell Damage in HCM and C2C12 Cells (S51); FIGURE 1 legend (S116, S117)
cell viability: cell viability; comparator: normal culture medium without addition of any statins — Materials and Methods > Cell Viability Assay (S8); Results > Ferroptosis Contributes to Atorvastatin-Induced Cell Damage in HCM and C2C12 Cells (S51); FIGURE 1 legend (S116)